Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | TACR3 | P29371 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | BMPR1B | O00238 | 2/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.31 |
| ▸ | KDR | P35968 | 2/20 | 0.31 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.31 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.31 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL475667 | 0.78 | CHRM2 (0.44) | CHRNB2 | |
| SCHEMBL475670 | 0.78 | CHRM2 (0.44) | CHRNB2 | |
| SCHEMBL2573700 | 0.73 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3TACR3CHRNB2 | |
| SCHEMBL13407530 | 0.72 | HTR2A (0.39) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12900582 | 0.71 | CHRM2 (0.36) | CHRNB2CHRNA5CHRNB4CHRNA3BMPR1B | |
| SCHEMBL6764229 | 0.70 | BMPR1B (0.33) | PARP1BMPR1BPDGFRBKDRACVR1B | |
| SCHEMBL30515590 | 0.69 | CYP1A2 (0.32) | — | |
| SCHEMBL5088449 | 0.67 | CCR1 (0.39) | PARP1BMPR1BPDGFRBKDRACVR1B | |
| SCHEMBL12900540 | 0.67 | ROCK2 (0.35) | PARP1ROCK2ROCK1 | |
| SCHEMBL15046892 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034469-A1 | Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034469-A1 | Heterocyclic Compound | BIRC5, XIAP, BIRC2 | SLC6A2 401/4885SLC6A4 1305/4885SLC6A3 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.